Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Oncology
Vol. 3, Issue 2, 2016
October 21, 2015 EDT
Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
Gabriel Tremblay
,
Unnati Majethia
,
Ilias Kontoudis
,
Jesús De Rosendo
,
spain
cost-utility
cost-effectiveness
eribulin
her2-negative
metastatic breast cancer
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9834
Photo by
Ken Treloar
on
Unsplash
JHEOR
1.
Tremblay G, Majethia U, Kontoudis I, De Rosendo J. Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy.
JHEOR
. 2015;3(2):180-193.
doi:10.36469/9834
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats